Primary Sclerosing Cholangitis. Obstruction of bile duct
Conditions
Interventions
Intervention 1: Intervention group: Recipient of inositol supplement 800 mg/day for three months. Intervention 2: Intervention group: placebo.
Sponsors
Shahid Beheshti University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: cholestatic liver disease for at least 6 months serum alkaline phosphatase levels 1.5 times the normal upper limit
Exclusion criteria
Exclusion criteria: co-existing liver diseases such as alcoholic liver disease and NAFLD, autoimmune hepatitis, chronic B or C hepatitis, PBC, hemochromatosis, Wilson's disease, congenital biliary disease, and cholangiocarcinoma
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Alanine transaminase. Timepoint: before intervention and 3 month later. Method of measurement: blood test.;Aspartate aminotransferase. Timepoint: before intervention and 3 month later. Method of measurement: blood test.;Albumin. Timepoint: before intervention and 3 month later. Method of measurement: blood test.;Bilirubin. Timepoint: before intervention and 3 month later. Method of measurement: blood test.;Alkaline Phosphatase. Timepoint: before intervention and 3 month later. Method of measurement: blood test.;Alleviation of prutrius. Timepoint: before intervention and 3 month later. Method of measurement: physical examination. | — |
Secondary
| Measure | Time frame |
|---|---|
| A decline in the Mayo Risk Score of patients. Timepoint: before intervention and 3 months later. Method of measurement: Mayo Risk scale measurement. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactElham Mortazavi
Shahid Beheshti University of Medical Sciences
Outcome results
None listed